(2R)-3-hydroxy-2-[(2-methylpropan-2-yl)oxycarbonylamino]propanoic acid

We are (2R)-3-hydroxy-2-[(2-methylpropan-2-yl)oxycarbonylamino]propanoic acid CAS:6368-20-3 manufacturer and supplier in China, Pls send inquiry of to info@nbinno.com of visit www.nbinno.com our official website should you have any interests

Chemical Name:(2R)-3-hydroxy-2-[(2-methylpropan-2-yl)oxycarbonylamino]propanoic acid
CAS.NO:6368-20-3
Synonyms:(2R)-3-hydroxy-2-[(2-methylpropan-2-yl)oxycarbonylamino]propanoic acid
(R)-N-Boc-D-serine
Boc-L-Ser-OH
(R)-t-Boc-serine
N-t-Boc-D-Serine
N-t-butyloxycarbonyl-D-serine
 
Physical and Chemical Properties:
Density 1.2±0.1 g/cm3
Boiling Point 385.1±37.0 °C at 760 mmHg
Melting Point 91-95 °C
Molecular Formula C8H15NO5
Molecular Weight 205.208
Flash Point 186.7±26.5 °C
Vapour Pressure 0.0±2.0 mmHg at 25°C
Index of Refraction 1.486
 
Specification:
Appearance:White to off-white powder 
Assay:≥98.0%
Specific Rotation:+7.5°~+9.5°(on dried basis C=1,in water) 
Loss on Drying :≤1.0%
Melting Point85-95°C
Other single unknown impurity:≤0.5%
Total impurities:≤2.0%
Chiral impurity:≤0.5%
 
Packing:25 kg/drum, can also be packaged according to customer requirements
Storage:Store in a cool, ventilated place
Application:Intermediate of Lacosamide(CAS:175481-36-4).

(2R)-3-hydroxy-2-[(2-methylpropan-2-yl)oxycarbonylamino]propanoic acid


Related News: Only when the drug substance is processed into a pharmaceutical preparation can it become a drug for clinical application.5,6-Dibromopyridine-3-carboxylic acid Only when the drug substance is processed into a pharmaceutical preparation can it become a drug for clinical application.1978-38-7 This means that the drug attributes of the drug substance will be lost in the future, and the monopoly power of some drug substances will also be lost. The preparation company will become the main person in charge of the drug. The drug preparation company will be responsible for the quality of the original excipients. It will be more cautious, some raw and auxiliary materials companies whose quality cannot be guaranteed will be gradually eliminated, and the industry concentration will be further improved.1-cloro-2-fluoro-3-isocianatobenceno CAS:69922-25-4 This means that the drug attributes of the drug substance will be lost in the future, and the monopoly power of some drug substances will also be lost. The preparation company will become the main person in charge of the drug. The drug preparation company will be responsible for the quality of the original excipients. It will be more cautious, some raw and auxiliary materials companies whose quality cannot be guaranteed will be gradually eliminated, and the industry concentration will be further improved.The use of contrast agents is different from other drugs, and it needs to be used with corresponding equipment. In recent years, China is in the growth period of imaging equipment.

Related Products
Product Name
Diethyl Fluoromalonate Cas:685-88-1 View Details
3,5-Difluorotoluene View Details
Glyceryl Monooleate Cas:111-03-5 View Details
2-hydroxyacetophenone Cas:582-24-1 manufacturer Pyrrolo[2,1-f][1,2,4]triazin-4-amine Cas:159326-68-8 manufacturer 3,3′-DIINDOLYLMETHANE Cas:1968-5-4 manufacturer 1-Hydroxybenzotriazole Cas:2592-95-2 manufacturer Methyl 4-chloro-3-oxo-butanoate Cas:32807-28-6 manufacturer